^
Association details:
| Biomarker: | RET fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | HA121-28 (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of HA121-28 in Patients With Non-Small Cell Lung Cancer
Excerpt:
...RET gene fusion, as demonstrated by "Next-generation" sequencing(NGS) method in central laboratory with College of American Pathologists(CAP) or Clinical Laboratory Improvement Amendments(CLIA) certification; 5....
Trial ID:
Source:
Title:
1329P - A single-arm, open-label, multi-center, phase I study of HA121-28 in patients with advanced solid tumors
Published date:
09/13/2021
Excerpt:
Among 17 pts (8 males), median age 49 (range 40-71) with RET fusion+ NSCLC (2 with 450 mg, 13 with 600 mg, 2 with 800 mg), 11 (64%) had been heavily pretreated (≥ 2 prior lines)….The ORR of RET fusion+ NSCLC pts was 41% (95% CI: 18-67%, 7 PRs) and DCR was 82% (95% CI: 56-96%, 7 SDs) by investigators....HA121-28 showed a tolerable safety profile with encouraging efficacy among RET fusion+ NSCLC pts.
Trial ID:
